# GIMEMA ALL2820 (NCT04722848)

> Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

No report yet. It can be ordered.

- Drugs tested: ponatinib plus blinatumomab
- Indication: newly diagnosed adult Ph+ ALL

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04722848
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
- Conditions: Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive); ALL, Adult; Philadelphia-Positive ALL
- Interventions: Ponatinib + Blinatumomab; Chemotherapy + Imatinib
- Enrollment: 236
- Primary outcome: Number of patients who are event-free

## Indexed commentary on GIMEMA ALL2820 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 22
- YouTube: 1
- Podcasts: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=gimema-all2820-nct04722848

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04722848", "email": "<work email>"}; the inbox owner confirms by the emailed link.